Lotrimin, Tinactin Spray Products Recalled Due to Presence of Benzene
Lotrimin and Tinactin spray products are over the counter topical antifungals.
Fungal Infections
Treatment for Pneumocystis Pneumonia Recalled Due to Temperature Control Issue
The recall was initiated because the product had prolonged exposure to extremely cold weather during shipment.
Oteseconazole Gets Priority Review for Recurrent Vulvovaginal Candidiasis
The NDA submission is supported by data from three phase 3 trials, which included 2 global studies and one US-focused study.
‘Superbug’ Fungus Spreads Among Vulnerable in 2 US Cities
There were 101 Candida auris cases at a nursing home and 22 cases at hospitals from January to April
Brexafemme Approved for Vulvovaginal Candidiasis
The approval was based on data from two phase 3 trials that compared Brexafemme to placebo in female patients aged 12 years and older with acute VVC.
Oteseconazole Promising for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a novel oral inhibitor of fungal CYP51.
Ibrexafungerp Gets Priority Review for Vulvovaginal Candidiasis
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Ibrexafungerp NDA for Vulvovaginal Candidiasis Submitted for Review
Ibrexafungerp is an investigational oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections
Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.
